Rifampin Similar to Isoniazid for Preventing Active Tuberculosis
Rifampin has significantly higher rate of treatment completion, fewer drug-related adverse events.
Treatments
Nemolizumab Effective for Moderate, Severe Atopic Dermatitis Inadequately Controlled With Topical Therapy
For patients with moderate to severe atopic dermatitis inadequately controlled with topical therapies, the anti-IL-31 receptor A humanized monoclonal antibody nemolizumab may provide benefit.
Guidelines for ART Updated for Those With or at Risk for HIV
ART recommended for almost all HIV-infected; should be initiated as soon as possible post diagnosis.
Basal Insulin Analogs vs NPH Insulin to Reduce Hypoglycemia-Linked ED Visits in T2D
Compared with human neutral protamine Hagedorn insulin, basal insulin analogs do not reduce risk of hypoglycemia-linked ED visits or hospital admissions in T2D.
L-Glutamine Oral Therapy Reduces Sickle Cell-Related Pain Better Than Placebo
L-Glutamine oral treatment with or without hydroxyurea reduces pain crises better than placebo in individuals with sickle cell disease.
Single High-Dose Liposomal Amphotericin B Effectively Treats HIV-Associated Cryptococcal Meningitis
Single high-dose liposomal amphotericin B (L-AmB) is non-inferior to daily dosed L-AmB at the standard dose in treatment of fungal clearance in HIV-associated cryptococcal meningitis.
Chemotherapy With Bevacizumab May Improve Some Ovarian Cancer Outcomes, Worsen Others
First-line chemotherapy in combination with bevacizumab, compared with chemotherapy alone, may benefit patients with ovarian cancer and elevated neutrophil-to-lymphocyte ratios.
Is New Surveillance Monitoring Required for Enterococcal Oxazolidinone Resistance?
A study was conducted to evaluate the oxazolidinone resistance mechanisms of enterococci bacteria.
Avastin Plus ChemoTx Approved for Advanced Ovarian Cancer After Resection
Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).
Weighing the Risks of Deep Brain Stimulation
DBS has been known to generate other movement-related disorders such as dyskinesias, blepharospasm, and hypokinesia.
Next post in Neurology Information Center
